Dermal Safety Trial of Ztilido (Lidocaine patch 1.8%) for the Treatment of Postherpetic Neuralgia
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2014
Price : $35 *
At a glance
- Drugs Lidocaine (Primary)
- Indications Postherpetic neuralgia
- Focus Adverse reactions
- 11 Aug 2014 This trial is expected to be completed by November 2014, and a New Drug Application is expected to be filed in the first quarter of 2015, according to a Scilex Pharmaceuticals media release.
- 11 Aug 2014 Status changed from recruiting to active, no longer recruiting, according to a Scilex Pharmaceuticals media release.
- 14 Jul 2014 Status changed from planning to recruiting according to the Scilex Pharmaceuticals media release.